Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Innovent Biologics (HKEX: 01801) and WeComput have announced a strategic partnership to advance AI-driven drug discovery and development. The collaboration aims to combine their respective strengths and technologies to accelerate the drug R&D process using AI technology. Innovent Academy will utilize WeComput's WeMol molecular design platform to enhance its computing infrastructure, while WeMol will integrate NVIDIA's BioNeMo to expand Innovent's AI systems' computing capability.
This partnership is expected to create a comprehensive, efficient, and intelligent AI-driven drug discovery system. The collaboration aims to reduce costs, shorten R&D cycles, and improve success rates in drug development, ultimately delivering more innovative treatments to patients.
Innovent Biologics (HKEX: 01801) e WeComput hanno annunciato una partnership strategica per avanzare nella scoperta e nello sviluppo di farmaci guidati dall'AI. La collaborazione mira a combinare i rispettivi punti di forza e tecnologie per accelerare il processo di R&S farmaceutica utilizzando la tecnologia AI. Innovent Academy utilizzerà la piattaforma di design molecolare WeMol di WeComput per migliorare la propria infrastruttura di calcolo, mentre WeMol integrerà BioNeMo di NVIDIA per espandere le capacità di calcolo dei sistemi AI di Innovent.
Questa partnership è prevista per creare un sistema di scoperta di farmaci completo, efficiente e intelligente guidato dall'AI. La collaborazione si propone di ridurre i costi, abbreviare i cicli di R&S e migliorare i tassi di successo nello sviluppo di farmaci, portando infine a trattamenti più innovativi per i pazienti.
Innovent Biologics (HKEX: 01801) y WeComput han anunciado una asociación estratégica para avanzar en la descubrimiento y desarrollo de medicamentos impulsados por IA. La colaboración tiene como objetivo combinar sus respectivas fortalezas y tecnologías para acelerar el proceso de I+D farmacéutica utilizando tecnología de IA. Innovent Academy utilizará la plataforma de diseño molecular WeMol de WeComput para mejorar su infraestructura de computación, mientras que WeMol integrará BioNeMo de NVIDIA para expandir la capacidad de computación de los sistemas de IA de Innovent.
Se espera que esta asociación cree un sistema integral, eficiente e inteligente de descubrimiento de medicamentos impulsado por IA. La colaboración tiene como objetivo reducir costos, acortar los ciclos de I+D y mejorar las tasas de éxito en el desarrollo de medicamentos, entregando en última instancia tratamientos más innovadores a los pacientes.
Innovent Biologics (HKEX: 01801)와 WeComput는 AI 기반의 약물 발견 및 개발을 진전시키기 위한 전략적 파트너십을 발표했습니다. 이 협력은 AI 기술을 사용하여 약물 연구 및 개발 프로세스를 가속화하기 위해 각각의 강점과 기술을 결합하는 것을 목표로 합니다. Innovent Academy는 WeComput의 WeMol 분자 디자인 플랫폼을 활용하여 컴퓨팅 인프라를 강화하고, WeMol은 NVIDIA의 BioNeMo를 통합하여 Innovent의 AI 시스템의 컴퓨팅 능력을 확장할 것입니다.
이 파트너십은 포괄적이고 효율적이며 지능적인 AI 기반 약물 발견 시스템을 창출할 것으로 기대됩니다. 협력의 목표는 비용을 줄이고, R&D 주기를 단축하며, 성공 확률을 향상시키는 것이며, 궁극적으로 환자에게 보다 혁신적인 치료를 제공하는 것입니다.
Innovent Biologics (HKEX: 01801) et WeComput ont annoncé un partenariat stratégique pour faire avancer la découverte et le développement de médicaments pilotés par l'IA. La collaboration vise à combiner leurs forces et technologies respectives pour accélérer le processus de R&D pharmaceutique en utilisant la technologie de l'IA. Innovent Academy utilisera la plateforme de conception moléculaire WeMol de WeComput pour améliorer son infrastructure de calcul, tandis que WeMol intégrera BioNeMo de NVIDIA pour élargir la capacité de calcul des systèmes d'IA d'Innovent.
Ce partenariat devrait créer un système de découverte de médicaments complet, efficace et intelligent basé sur l'IA. La collaboration vise à réduire les coûts, raccourcir les cycles de R&D et améliorer les taux de succès dans le développement de médicaments, livrant finalement des traitements plus innovants aux patients.
Innovent Biologics (HKEX: 01801) und WeComput haben eine strategische Partnerschaft angekündigt, um mit KI unterstützte Arzneimittelentdeckung und -entwicklung voranzutreiben. Die Zusammenarbeit zielt darauf ab, ihre jeweiligen Stärken und Technologien zu kombinieren, um den Arzneimittelforschungs- und -entwicklungsprozess mithilfe von KI-Technologie zu beschleunigen. Innovent Academy wird die WeMol-Moleküldesign-Plattform von WeComput nutzen, um ihre Recheninfrastruktur zu verbessern, während WeMol NVIDIAs BioNeMo integrieren wird, um die Rechenfähigkeit der KI-Systeme von Innovent zu erweitern.
Erwartet wird, dass diese Partnerschaft ein umfassendes, effizientes und intelligentes KI-gestütztes Arzneimittelentdeckungssystem schafft. Die Zusammenarbeit zielt darauf ab, Kosten zu senken, Forschungs- und Entwicklungszyklen zu verkürzen und die Erfolgsquote bei der Arzneimittelentwicklung zu verbessern und letztendlich innovativere Behandlungen für Patienten bereitzustellen.
- Strategic partnership with WeComput to advance AI-driven drug discovery
- Integration of WeComput's WeMol platform to enhance computing infrastructure
- Incorporation of NVIDIA's BioNeMo to expand AI computing capabilities
- Potential reduction in AI implementation and experimental costs
- Expected shortening of drug R&D cycle and improved R&D success rate
- None.
SAN FRANCISCO and
As an important R&D engine of Innovent, Innovent Academy has been deeply exploring and actively deploying AI drug research and development. In this collaboration, Innovent Academy will utilize WeComput's WeMol, a molecular design platform, to build and enhance its computing infrastructure, accelerating the drug research and development process. Meanwhile, WeMol will integrate NVIDIA's BioNeMo to further expand the computing capability of Innovent's AI systems and improve computational efficiency.
Innovent and WeMol will integrate their technological strengths to create a comprehensive AI-driven drug discovery and development system that is efficient, user-friendly, digitalized, intelligent and automated. This cooperation will allow Innovent to significantly reduce AI implementation and experimental costs, shorten the drug R&D cycle, improve R&D success rate, and deliver more innovative drugs and treatment options to patients.
Dr. Kaijie He, Vice President of Oncology Biology and ADC Drug Research, said, "AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to partner with WeComput and integrate advanced AI technology to boost our R&D capabilities and expedite the discovery and development of innovative drugs. We believe this collaboration will offer robust technical support to our research team, propelling us toward greater breakthroughs in the global pharmaceutical market."
Harry (Hu) Ge, CEO of WeComput, stated, "This collaboration will be mutually beneficial, fostering the widespread application of AI technology in the biopharmaceutical sector and driving innovation and development in the global pharmaceutical industry."
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 10 products in the market. It has 4 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
About WeComput
WeComput is dedicated to "computational technology driving innovative drug research and development." With a profound understanding of the innovative drug development process, WeComput integrates artificial intelligence, biophysics, and high-performance computing technologies to create a unique digital, intelligent and automated platform for drug molecule generation, design and simulation. This platform is poised to revolutionize traditional drug discovery methods and drive the research and development of innovative drugs such as antibodies, proteins, small molecules and mRNA. The parent company, Beijing Zhongda Weixin Technology Co., Ltd., was registered in 2015 and has been recognized as a national high-tech enterprise. In 2021, it received equity investment from Sequoia Capital and was selected as a senior member of the NVIDIA Inception program. To date, WeComput has served hundreds of clients worldwide, including numerous biopharmaceutical companies, universities, hospitals, and research institutions, and has independently developed the leading drug molecule design and intelligent computing platform, WeMol.
View original content:https://www.prnewswire.com/news-releases/innovent-and-wecomput-announce-strategic-partnership-to-advance-ai-driven-drug-discovery-and-development-302207255.html
SOURCE Innovent Biologics
FAQ
What is the purpose of Innovent Biologics' partnership with WeComput?
How will WeComput's WeMol platform benefit Innovent Biologics?
What are the expected benefits of this AI-driven collaboration for Innovent Biologics?
How does NVIDIA's BioNeMo fit into the partnership between Innovent Biologics and WeComput?
